二甲双胍降低2型糖尿病患者肝癌风险的Meta-分析

Metformin use improves survival of diabetic liver cancer patients: a Metaanalysis

目的评估二甲双胍治疗2型糖尿病患者罹患肝癌的风险。方法从PubMed、Embase、中国期刊全文数据库(CNKI)、维普全文数据库(VIP)万方等数据库获得关于二甲双胍与糖尿病患者罹患肝癌风险的相关研究,评价二甲双胍治疗糖尿病过程中,患者罹患肝癌的风险,检索时限为从建库至2017年12月。结果共纳入11篇相关文献,其中病例对照研究8篇,队列研究3篇;共计123 412例患者,其中实验组78 817例,对照组44 595例。病例对照研究Meta-分析结果显示,与其他降糖药相比,二甲双胍治疗可使2型糖尿病患者肝癌发病风险降低42%[RR=0.58,95%CI(0.52,0.65),P=0.000 01];队列研究Meta-分析结果则显示,二甲双胍治疗可使2型糖尿病患者肝癌发病风险降低47%[RR=0.53,95%CI(0.13,2.21),P=0.38]。结论二甲双胍治疗可降低2型糖尿病患者罹患肝癌的风险。

Objective To evaluate the risk of morbidity of liver cancer in type 2 diabetes treated with metformin. Methods The cohort studies and case-control studies in evaluating the effect of metformin on liver cancer in type 2 diabetes were researched from PubMed, Embase, CNKI, VIP and Wanfang Data until December 2016. Results A total of 11 articles were included, eight of which were case-control studies and three were cohort studies. A total of 123 412 patients, including 78 817 patients in the experimental group and 44 595 cases in the control group. Meta-analysis of case-control studies showed that metformin treatment can reduce the risk of morbidity of liver cancer in type 2 diabetes by 42%[RR=0.58, 95%CI(0.52, 0.65), P=0.000 01] compared with other antidiabetic drugs; the results from the cohort studies showed that metformin therapy can reduce the risk of morbidity of liver cancer in type 2 diabetes patients by 47%[RR=0.53, 95%CI(0.13, 2.21), P=0.38] compared with those with other antidiabetic drugs. Conclusion Metformin therapy can reduce the risk of morbidity of liver cancer in patients with type 2 diabetes.